155 related articles for article (PubMed ID: 22087174)
1. Cytogenetic methods for detection of oxidative stress and evaluation of antioxidant therapy in hepatitis C infection.
Emerit I
Hepat Mon; 2011 Jun; 11(6):434-9. PubMed ID: 22087174
[TBL] [Abstract][Full Text] [Related]
2. Clastogenic factors in the plasma of patients with hepatitis C: their possible role at the origin of hepatocarcinoma.
Emerit I; Serejo F; Carneiro de Moura M
Cancer Genet Cytogenet; 2007 Nov; 179(1):31-5. PubMed ID: 17981212
[TBL] [Abstract][Full Text] [Related]
3. Clastogenic factors as biomarkers of oxidative stress in chronic hepatitis C.
Emerit I; Serejo F; Filipe P; Alaoui Youssefi A; Fernandes A; Costa A; Freitas J; Ramalho F; Baptista A; Carneiro de Moura M
Digestion; 2000; 62(2-3):200-7. PubMed ID: 11025369
[TBL] [Abstract][Full Text] [Related]
4. [Investigation of oxidative stress and antioxidant defense in patients with hepatitis B virus infection and the effect of interferon-alpha plus lamivudine combination therapy on oxidative stress].
Acar A; Görenek L; Aydin A; Eyigün CP; Eken A; Sayal A; Pahsa A
Mikrobiyol Bul; 2009 Jul; 43(3):411-23. PubMed ID: 19795616
[TBL] [Abstract][Full Text] [Related]
5. Clastogenic factors as potential biomarkers of increased superoxide production.
Emerit I
Biomark Insights; 2007 Dec; 2():429-38. PubMed ID: 19662223
[TBL] [Abstract][Full Text] [Related]
6. Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy.
Levent G; Ali A; Ahmet A; Polat EC; Aytaç C; Ayşe E; Ahmet S
J Transl Med; 2006 Jun; 4():25. PubMed ID: 16787540
[TBL] [Abstract][Full Text] [Related]
7. Clastogenic factors in plasma of HIV-1 infected patients.
Fuchs J; Emerit I; Levy A; Cernajvski L; Schöfer H; Milbradt R
Free Radic Biol Med; 1995 Dec; 19(6):843-8. PubMed ID: 8582657
[TBL] [Abstract][Full Text] [Related]
8. [Effects of supplementation with the antioxidant flavonoid, silymarin, in chronic hepatitis C patients treated with peg-interferon + ribavirin. A placebo-controlled double blind study].
Pár A; Roth E; Miseta A; Hegedüs G; Pár G; Hunyady B; Vincze A
Orv Hetil; 2009 Jan; 150(2):73-9. PubMed ID: 19103558
[TBL] [Abstract][Full Text] [Related]
9. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin.
Ahmad J; Dodson SF; Demetris AJ; Fung JJ; Shakil AO
Liver Transpl; 2001 Oct; 7(10):863-9. PubMed ID: 11679984
[TBL] [Abstract][Full Text] [Related]
10. Oxidative stress in chronic hepatitis C: a preliminary study on the protective effects of antioxidant flavonoids.
Emerit I; Huang CY; Serejo F; Filipe P; Fernandes A; Costa A; Freitas J; Baptista A; Carneiro de Moura M
Hepatogastroenterology; 2005; 52(62):530-6. PubMed ID: 15816472
[TBL] [Abstract][Full Text] [Related]
11. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference.
Shamliyan TA; MacDonald R; Shaukat A; Taylor BC; Yuan JM; Johnson JR; Tacklind J; Rutks I; Kane RL; Wilt TJ
Ann Intern Med; 2009 Jan; 150(2):111-24. PubMed ID: 19124812
[TBL] [Abstract][Full Text] [Related]
12. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
13. Familial Mediterranean fever: clastogenic plasma factors correlated with increased O2(-)--production by neutrophils.
Sarkisian T; Emerit I; Arutyunyan R; Levy A; Cernjavski L; Filipe P
Hum Genet; 1997 Dec; 101(2):238-42. PubMed ID: 9402978
[TBL] [Abstract][Full Text] [Related]
14. Oxidative stress in Adamantiades-Behçet's disease.
Freitas JP; Filipe P; Yousefi A; Emerit I; Guerra Rodrigo F
Dermatology; 1998; 197(4):343-8. PubMed ID: 9873172
[TBL] [Abstract][Full Text] [Related]
15. Is delayed normalization of alanine aminotransferase a poor prognostic predictor in chronic hepatitis C patients treated with a combined interferon and ribavirin therapy?
Hung CH; Lee CM; Lu SN; Wang JH; Tung HD; Chen TM; Chen CH; Changchien CS
J Gastroenterol Hepatol; 2002 Dec; 17(12):1307-11. PubMed ID: 12423276
[TBL] [Abstract][Full Text] [Related]
16. Interferon/antioxidant combination therapy for chronic hepatitis C--a controlled pilot trial.
Look MP; Gerard A; Rao GS; Sudhop T; Fischer HP; Sauerbruch T; Spengler U
Antiviral Res; 1999 Sep; 43(2):113-22. PubMed ID: 10517313
[TBL] [Abstract][Full Text] [Related]
17. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism.
Carella C; Mazziotti G; Morisco F; Rotondi M; Cioffi M; Tuccillo C; Sorvillo F; Caporaso N; Amato G
Eur J Endocrinol; 2002 Jun; 146(6):743-9. PubMed ID: 12039693
[TBL] [Abstract][Full Text] [Related]
18. Effect of interferon, ribavirin and ursodeoxycholic acid in patients with hepatitis C infection.
Ljubuncic P; Konikoff FM; Blendis LM; Bomzon A
Hepatogastroenterology; 2005; 52(64):1191-6. PubMed ID: 16001659
[TBL] [Abstract][Full Text] [Related]
19. Management of chronic hepatitis B.
Wilt TJ; Shamliyan T; Shaukat A; Taylor BC; MacDonald R; Yuan JM; Johnson JR; Tacklind J; Rutks I; Kane RL
Evid Rep Technol Assess (Full Rep); 2008 Oct; (174):1-671. PubMed ID: 19408969
[TBL] [Abstract][Full Text] [Related]
20. Oxyradical-mediated clastogenic plasma factors in psoriasis: increase in clastogenic activity after PUVA.
Filipe P; Emerit I; Alaoui Youssefi A; Levy A; Cernjavski L; Freitas J; de Castro JL
Photochem Photobiol; 1997 Oct; 66(4):497-501. PubMed ID: 9337621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
